Payment overview · 2025
General Payments
$494.02
23 reported records · 12 companies
Healthcare provider profile · identity verified
Abdul Q Mohiuddin, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOPEWELL, VA · NPI 1003885575
Verified facts
What the public records show
CMS Open Payments records show Abdul Q Mohiuddin, MD received $494.02 in general payments during 2025 across 23 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 592 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 592 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $96.09 | 19.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.80 | 14.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.54 | 13.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $62.28 | 12.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.77 | 8.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.54 | 6.0% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $29.44 | 6.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.76 | 5.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.43 | 3.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.29 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.28 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.80 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.02 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $96.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.80 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $62.28 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.76 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 592 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
592 | 90 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
139 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
592 | 90 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1198 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 1102 | 224 |
| Eliquis | Apixaban | 592 | 90 |
| Furosemide | Furosemide | 585 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 522 | 145 |
| Carvedilol | Carvedilol | 384 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 365 | 88 |
| Potassium Chloride | Potassium Chloride | 364 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 353 | 70 |
| Hydralazine Hcl | Hydralazine Hcl | 352 | 92 |
| Losartan Potassium | Losartan Potassium | 330 | 81 |
| Trazodone Hcl | Trazodone Hcl | 330 | 78 |
| Lisinopril | Lisinopril | 311 | 75 |
| Metformin Hcl | Metformin Hcl | 302 | 55 |
| Sertraline Hcl | Sertraline Hcl | 302 | 60 |
| Divalproex Sodium | Divalproex Sodium | 295 | 47 |
| Mirtazapine | Mirtazapine | 290 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 282 | 70 |
| Levetiracetam | Levetiracetam | 280 | 41 |
| Omeprazole | Omeprazole | 272 | 58 |
| Donepezil Hcl | Donepezil Hcl | 219 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 33 |
| Spironolactone | Spironolactone | 204 | 45 |
| Buspirone Hcl | Buspirone Hcl | 201 | 36 |
| Jardiance | Empagliflozin | 199 | 36 |
| Memantine Hcl | Memantine Hcl | 186 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 182 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 174 | 36 |
| Baclofen | Baclofen | 173 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 71 |
| Prednisone | Prednisone | 140 | 93 |
| Trulicity | Dulaglutide | 139 | 26 |
| Clonidine Hcl | Clonidine Hcl | 138 | 28 |
| Allopurinol | Allopurinol | 131 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 120 | 38 |
| Famotidine | Famotidine | 112 | 29 |
| Gabapentin | Gabapentin | 110 | 45 |
| Januvia | Sitagliptin Phosphate | 110 | 16 |
| Montelukast Sodium | Montelukast Sodium | 107 | 29 |
| Midodrine Hcl | Midodrine Hcl | 106 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 22 |
| Topiramate | Topiramate | 102 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 16 |
| Simvastatin | Simvastatin | 95 | 16 |
| Latanoprost | Latanoprost | 92 | 23 |
| Xarelto | Rivaroxaban | 92 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 90 | 27 |
| Enulose | Lactulose | 90 | 14 |
| Risperidone | Risperidone | 90 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 24 |
| Farxiga | Dapagliflozin Propanediol | 88 | suppressed |
| Myrbetriq | Mirabegron | 88 | suppressed |
| Bumetanide | Bumetanide | 87 | 17 |
| Sucralfate | Sucralfate | 86 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 68 |
| Ezetimibe | Ezetimibe | 81 | 19 |
| Entresto | Sacubitril/Valsartan | 79 | 18 |
| Alendronate Sodium | Alendronate Sodium | 78 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 54 |
| Linzess | Linaclotide | 74 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 72 | 33 |
| Diltiazem 24hr Er | Diltiazem Hcl | 72 | suppressed |
| Finasteride | Finasteride | 72 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 71 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 25 |
| Lamotrigine | Lamotrigine | 69 | suppressed |
| Aripiprazole | Aripiprazole | 68 | 14 |
| Methocarbamol | Methocarbamol | 68 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 16 |
| Propranolol Hcl | Propranolol Hcl | 67 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 65 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 12 |
| Meloxicam | Meloxicam | 61 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 11 |
| Lithium Carbonate | Lithium Carbonate | 59 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 59 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 29 |
| Diltiazem Hcl | Diltiazem Hcl | 57 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 57 | 16 |
| Austedo | Deutetrabenazine | 55 | suppressed |
| Levofloxacin | Levofloxacin | 55 | 50 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 55 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 52 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 18 |
| Colchicine | Colchicine | 47 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 45 | suppressed |
| Olanzapine | Olanzapine | 43 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 20 |
| Tramadol Hcl | Tramadol Hcl | 42 | 26 |
| Brilinta | Ticagrelor | 41 | 12 |
| Celecoxib | Celecoxib | 41 | 11 |
| Clozapine | Clozapine | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Primidone | Primidone | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Glipizide | Glipizide | 38 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 14 |
| Ozempic | Semaglutide | 36 | suppressed |
| Phenytoin | Phenytoin | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 11 |
| Calcitriol | Calcitriol | 34 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Valproic Acid | Valproic Acid | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Nifedipine Er | Nifedipine | 33 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 12 |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 11 |
| Rytary | Carbidopa/Levodopa | 29 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Methimazole | Methimazole | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Desloratadine | Desloratadine | 26 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 11 |
| Admelog Solostar | Insulin Lispro | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Novolog | Insulin Aspart | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Nyamyc | Nystatin | 21 | 16 |
| Perphenazine | Perphenazine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Risperidone Odt | Risperidone | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | 12 |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $494.02 · 23 records | E.R. Squibb & Sons, L.L.C. | AIRSUPRA, AMYVID, BREZTRI, CAPLYTA, COBENFY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, KISUNLA, NURTEC ODT, Nayzilam, OTEZLA, REPATHA, TRELEGY ELLIPTA, XIFAXAN, YUPELRI, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error